{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals Stock Plummets to 52-Week Low of $4.23
Salarius Pharmaceuticals, Inc. has reached a new 52-week low, contrasting with its previous high. Despite a year-over-year performance increase, the company faces volatility and challenges in the industry. With a market cap of USD 2 million, it operates at a loss and has notable financial metrics that raise concerns.
Is Salarius Pharmaceuticals, Inc. overvalued or undervalued?
As of August 5, 2022, Salarius Pharmaceuticals, Inc. is considered overvalued with a significant downgrade in investment appeal due to its negative Return on Equity and poor stock performance, contrasting sharply with struggling peers.
Is Salarius Pharmaceuticals, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is neutral with mixed signals, as weekly indicators show mild bullishness while daily moving averages indicate short-term weakness.
Who are in the management team of Salarius Pharmaceuticals, Inc.?
As of March 2022, the management team of Salarius Pharmaceuticals, Inc. includes Dr. William McVicar (Chairman), Mr. David Arthur (CEO), Dr. Bruce McCreedy (Interim Chief Scientific Officer), Dr. Paul Lammers (Lead Independent Director), and several independent directors: Ms. Tess Burleson, Mr. Arnold Hanish, and Mr. Jonathan Lieber. They oversee the company's strategic direction and operations.
What does Salarius Pharmaceuticals, Inc. do?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted therapies for pediatric and other cancers. It has a market capitalization of $2.23 million and reported a net profit loss of $2 million as of March 2025.
How big is Salarius Pharmaceuticals, Inc.?
As of Jun 18, Salarius Pharmaceuticals, Inc. has a market capitalization of 2.23 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.56 million over the latest four quarters. As of Dec'24, shareholder's funds were 1.51 million and total assets were 3.02 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
